MCL1 and melanoma: The study demonstrated that none of the drugs showed significant effects on a stand-alone basis, while combinations of drugs targeting Mcl-1 and Bcl-xL had a synergistic ability to kill cancer cells, hence providing evidence of how Bcl-xL and Mcl-1 appear to be key factors in maintaining melanoma cell survival.